Search

Your search keyword '"David F. Stroncek"' showing total 553 results

Search Constraints

Start Over You searched for: Author "David F. Stroncek" Remove constraint Author: "David F. Stroncek" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
553 results on '"David F. Stroncek"'

Search Results

1. Deciphering the importance of culture pH on CD22 CAR T-cells characteristics

2. Expanding the reach of commercial cell therapies requires changes at medical centers

3. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output

4. Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors

5. Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products

6. Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases

7. Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy

8. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control

9. High efficiency closed-system gene transfer using automated spinoculation

10. Point-of-care cell therapy manufacturing; it’s not for everyone

11. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products

12. Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy

13. Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use

14. Single cell sequencing reveals gene expression signatures associated with bone marrow stromal cell subpopulations and time in culture

15. Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

16. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

17. Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System

18. Comparison of human bone marrow stromal cells cultured in human platelet growth factors and fetal bovine serum

19. Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules

20. Future perspectives in melanoma research 'Melanoma Bridge', Napoli, November 30th–3rd December 2016

21. Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument

22. Future perspectives in melanoma research

23. Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment

27. Supplementary Figures 1 - 12 and Tables 1 - 11 from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

28. Supplementary Materials and Methods from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest

29. Supplementary Data DS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

30. Data from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial

31. Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies

32. Supplemental Figure 3 from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients

36. Data from Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients

38. Intraperitoneal monocytes and interferons as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results of a phase I clinical trial

39. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

40. Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease

41. Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells

42. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

43. Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

44. Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

45. Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34+-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells

46. T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

47. Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease

48. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

49. Variations in novel cellular therapy products manufacturing

50. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Catalog

Books, media, physical & digital resources